Saphenous vein graft lesions: Are second-generation drug-eluting stents better?

Abstract

Long-term outcomes were similar in patients treated with first- or second-generation drug-eluting stents (DES) for saphenous vein graft (SVG) lesions. Patients presenting with acute myocardial infarction as a result of occluded SVG may derive some benefit from the use of second- versus first-generation DES Randomized clinical trials are needed to determine whether newer DES types including those with bioabsorbable polymer or scaffolds offer a distinct advantage in the treatment of SVG lesions.

• Authors: Dhaval Kolte, J Dawn Abbott
• Journal: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (Catheter Cardiovasc Interv) Vol. 87 Issue 1 Pg. 41-2 (Jan 01 2016) ISSN: 1522-726X [Electronic] United States
• PMID: 27410952 (Publication Type: Editorial)
• Copyright: © 2016 Wiley Periodicals, Inc.

Topics

• Drug-Eluting Stents
• Forecasting
• Graft Occlusion, Vascular (epidemiology)
• Humans
• Incidence
• Myocardial Infarction (surgery)
• Percutaneous Coronary Intervention
• Prosthesis Design
• Risk Assessment
• Risk Factors
• Saphenous Vein (transplantation)
• United States (epidemiology)